Ocugen(OCGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OCGN Ocugen

盘前交易 02-03 09:00:58 EST

1.43

-0.02

-1.38%

盘前1.47

+0.04+2.80%

08:55 EST

最高1.48	最低1.41	成交量334.31万
今开1.45	昨收1.45	日振幅4.83%
总市值4.69亿	流通市值4.39亿	总股本3.28亿
成交额482.89万	换手率1.09%	流通股本3.07亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OCGN","market":"US","secType":"STK","nameCN":"Ocugen","latestPrice":1.43,"timestamp":1770066000000,"preClose":1.45,"halted":0,"volume":3343096,"hourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.43,"latestTime":"08:55 EST","volume":7978,"amount":11653.2148886,"timestamp":1770126952123,"change":0.04,"changeRate":0.027972,"amplitude":0.027972},"delay":0,"changeRate":-0.013793103448275874,"floatShares":306730373,"shares":327888374,"eps":-0.217151,"marketStatus":"盘前交易","change":-0.02,"latestTime":"02-03 09:00:58 EST","open":1.45,"high":1.48,"low":1.41,"amount":4828892.5598808,"amplitude":0.048276,"askPrice":1.51,"askSize":50,"bidPrice":1.4,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.217151,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770129000000},"marketStatusCode":1,"adr":0,"listingDate":1417582800000,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.43,"latestTime":"08:55 EST","volume":7978,"amount":11653.2148886,"timestamp":1770126952123,"change":0.04,"changeRate":0.027972,"amplitude":0.027972},"postHourTrading":{"tag":"盘后","latestPrice":1.45,"preClose":1.43,"latestTime":"19:59 EST","volume":16373,"amount":23552.2981,"timestamp":1770080346838,"change":0.02,"changeRate":0.013986,"amplitude":0.020979},"volumeRatio":0.8209457494963495,"impliedVol":1.3123,"impliedVolPercentile":0.604},"requestUrl":"/m/hq/s/OCGN","defaultTab":"news","newsList":[{"id":"1146378224","title":"Ocugen公司完成2250万美元普通股承销注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1146378224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146378224?lang=zh_cn&edition=full","pubTime":"2026-01-23 21:01","pubTimestamp":1769173277,"startTime":"0","endTime":"0","summary":"生物医药企业Ocugen公司宣布，已完成总额达2250万美元的普通股承销注册直接发行。此次融资将助力公司推进眼科疾病、传染病等创新疗法的研发进程。通过注册直接发行方式，公司以定向增发形式向合格机构投资者募集资金，由承销商全额包销。该笔资金的到位将强化企业现金流状况，为管线药物临床研究提供资金保障。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","OCGN","BK4563","BK4139"],"gpt_icon":0},{"id":"2605459246","title":"Ocugen, Inc.盘中异动 大幅跳水8.08%报1.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605459246","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605459246?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:31","pubTimestamp":1769005886,"startTime":"0","endTime":"0","summary":"北京时间2026年01月21日22时31分，Ocugen, Inc.股票出现异动，股价大幅跳水8.08%。截至发稿，该股报1.54美元/股，成交量141.934万股，换手率0.45%，振幅3.59%。Ocugen, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121223126a4460f97&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260121223126a4460f97&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","OCGN","BK4568"],"gpt_icon":0},{"id":"2603964534","title":"Ocugen基因疗法显示能显著减缓AMD继发地图状萎缩的疾病进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603964534","media":"Minhua笔记","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603964534?lang=zh_cn&edition=full","pubTime":"2026-01-16 17:45","pubTimestamp":1768556712,"startTime":"0","endTime":"0","summary":"1月15日，美国生物技术公司Ocugen公布其AAV5基因疗法OCU410在ArMaDa II期试验的初步数据，显示该药显著减缓干性AMD继发GA病变进展。III 期临床试验计划Syfovre于2023年获得FDA批准用于治疗AMD继发的 GA，在最近一个季度财报中收入达1.51亿美元。Ocugen表示，计划在本季度晚些时候公布ArMaDa试验的完整数据，并于2026年启动III期临床试验，可能在2028年提交OCU410的上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116175647a7227f74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260116175647a7227f74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2458330169.SGD","LU0823434583.USD","LU0823434740.USD","LU0823421333.USD","LU0274383776.USD","LU1861559042.SGD","LU1861558580.USD","LU0081259029.USD","LU2098885051.SGD","LU1242518931.SGD","LU0082616367.USD","LU1316542783.SGD","LU2054465674.USD","BK4563","LU1951198990.SGD","BK4141","LU0823421416.USD","IE0009356076.USD","BK4585","BK4573","BK4588","LU1852331112.SGD","LU0198837287.USD","LU1951200564.SGD","LU2089985449.USD","BK4543","LU1064131342.USD","BK4532","LU0889565833.HKD","BK4512","LU2458330243.SGD","OCGN","LU1988902786.USD","LU0390134368.USD","LU0056508442.USD","LU1989764664.SGD","LU2264538146.SGD","IE00BMPRXR70.SGD","LU2360106780.USD","LU2931357623.SGD","IE00BMPRXN33.USD","LU2250418816.HKD","IE00B5949003.HKD","BK4529","BK4614","LU0127658192.USD","LU0642271901.SGD","LU1242518857.USD","LU1303367103.USD","BK4566","BK4534","LU0109392836.USD","LU0979878070.USD","AMD","BK4554","LU1803068979.SGD","BK4139","BK4605","LU1880398471.USD","LU1923623000.USD","BK4612","LU2355687059.USD","BK4575","LU0719512351.SGD","BK4568","IE0004445239.USD","LU1880398554.USD"],"gpt_icon":0},{"id":"2603679899","title":"Ocugen, Inc.盘中异动 快速下跌5.85%报1.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603679899","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603679899?lang=zh_cn&edition=full","pubTime":"2026-01-15 22:30","pubTimestamp":1768487431,"startTime":"0","endTime":"0","summary":"北京时间2026年01月15日22时30分，Ocugen, Inc.股票出现异动，股价大幅跳水5.85%。Ocugen, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Ocular Therapeutix, Inc.、Gt Biopharma, Inc.、Vyome Holdings, Inc.涨幅较大，Gt Biopharma, Inc.、Applied Therapeutics, Inc.、Hoth Therapeutics, Inc.较为活跃，换手率分别为46.17%、42.29%、12.82%，振幅较大的相关个股有Vyome Holdings, Inc.、Metavia Inc.、Foghorn Therapeutics Inc.，振幅分别为6.62%、5.54%、4.28%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522303297a1fc38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026011522303297a1fc38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCGN","BK4568","BK4563","BK4139"],"gpt_icon":0},{"id":"1118289206","title":"Ocugen公司：OCU410生物制剂许可申请计划于2028年如期推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1118289206","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118289206?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:18","pubTimestamp":1768483091,"startTime":"0","endTime":"0","summary":"Ocugen公司宣布，针对其候选疗法OCU410的生物制剂许可申请计划仍按既定时间表推进，预计将在2028年提交相关申请材料。这一进展标志着公司在眼科治疗领域的研发管线取得重要阶段性成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN","BK4568","BK4563","BK4139"],"gpt_icon":0},{"id":"1132953038","title":"Ocugen公布Ocu410修饰基因疗法针对干性年龄相关性黄斑变性继发地图样萎缩的积极二期初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1132953038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132953038?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:17","pubTimestamp":1768483045,"startTime":"0","endTime":"0","summary":"Ocugen公司近日发布了其Ocu410修饰基因疗法在治疗干性年龄相关性黄斑变性继发地图样萎缩的二期临床试验中取得的积极初步数据。该疗法展现出良好的安全性与耐受性特征，为患者提供了新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4563","BK4139","OCGN"],"gpt_icon":0},{"id":"1172820694","title":"Ocugen公司：本季度末将公布OCU410二期临床试验完整数据，计划于2026年启动三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1172820694","media":"美股速递","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172820694?lang=zh_cn&edition=full","pubTime":"2026-01-15 21:17","pubTimestamp":1768483042,"startTime":"0","endTime":"0","summary":"Ocugen公司宣布，其针对OCU410的二期临床试验完整数据集将于本季度末正式对外公布。根据公司最新规划，后续的三期临床试验预计在2026年正式启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN","BK4568","BK4139","BK4563"],"gpt_icon":0},{"id":"2595755849","title":"Ocugen, Inc.盘中异动 早盘股价大涨5.15%报1.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2595755849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595755849?lang=zh_cn&edition=full","pubTime":"2025-12-30 00:06","pubTimestamp":1767024401,"startTime":"0","endTime":"0","summary":"北京时间2025年12月30日00时06分，Ocugen, Inc.股票出现异动，股价急速上涨5.15%。截至发稿，该股报1.48美元/股，成交量97.4296万股，换手率0.31%，振幅6.56%。Ocugen, Inc.股票所在的生物技术行业中，整体跌幅为0.31%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025123000064197a0d159&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025123000064197a0d159&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","BK4563","OCGN"],"gpt_icon":0},{"id":"1138163725","title":"Ocugen第三季度运营利润为-1762.5万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138163725","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138163725?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:40","pubTimestamp":1763570429,"startTime":"0","endTime":"0","summary":"11月5日（路透社）- Ocugen第三季度收入为175.2万美元，而IBES预期为55万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN","BK4568","BK4139","BK4563"],"gpt_icon":0},{"id":"1112062863","title":"Ocugen 2025年第三季度业绩会总结及问答精华：基因疗法进展与全球市场布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1112062863","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112062863?lang=zh_cn&edition=full","pubTime":"2025-11-06 00:16","pubTimestamp":1762359385,"startTime":"0","endTime":"0","summary":"OCU410的欧洲监管接受美国试验设计，简化了提交时间表。韩国的监管机构预计将在美国授权后迅速进入市场。OCU410SD的二至三期中期数据预计将在2026年中期公布。截至2025年9月30日，公司现金余额为3290万美元，第三季度融资后预计运营资金可持续至2026年。Ocugen在基因疗法领域取得了显著进展，特别是在OCU400和OCU410的开发和市场准备方面。尽管面临一些风险，管理层对未来的商业化和临床进展充满信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"gpt_icon":0},{"id":"1130974844","title":"Ocugen公司：将在2026年第一季度发布Ocu410二期临床试验的完整数据，并于2026年开始三期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1130974844","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130974844?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:32","pubTimestamp":1762342357,"startTime":"0","endTime":"0","summary":"Ocugen公司：将在2026年第一季度发布Ocu410二期临床试验的完整数据，并于2026年开始三期试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4563","OCGN"],"gpt_icon":0},{"id":"2570038969","title":"Ocugen, Inc.盘中异动 快速拉升6.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570038969","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570038969?lang=zh_cn&edition=full","pubTime":"2025-09-24 21:42","pubTimestamp":1758721350,"startTime":"0","endTime":"0","summary":"北京时间2025年09月24日21时42分，Ocugen, Inc.股票出现波动，股价急速上涨6.02%。Ocugen, Inc.股票所在的生物技术行业中，整体跌幅为0.04%。其相关个股中，Uniqure N.V.、Osr Holdings Inc C/Wts 09/02/2028 、Cyclerion Therapeutics, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Jaguar Health, Inc.、Uniqure N.V.较为活跃，换手率分别为345.75%、35.37%、27.21%，振幅较大的相关个股有Uniqure N.V.、Pharmacyte  Biotech, Inc.、Briacell Therapeutics Corp C/Wts 26/02/2026，振幅分别为35.58%、28.69%、20.87%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214230a4413ff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250924214230a4413ff2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","OCGN","BK4563","BK4568"],"gpt_icon":0},{"id":"1135309654","title":"Ocugen公司与韩国广东制药完成OCU400视网膜色素变性调节性基因疗法许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1135309654","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135309654?lang=zh_cn&edition=full","pubTime":"2025-09-15 18:04","pubTimestamp":1757930679,"startTime":"0","endTime":"0","summary":"Ocugen公司与韩国广东制药株式会社宣布完成OCU400调节性基因疗法的许可协议，该疗法用于治疗视网膜色素变性疾病，协议涵盖韩国市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OCGN","BK4563","BK4568"],"gpt_icon":0},{"id":"2558502923","title":"Ocugen, Inc.2025财年第二财季实现净利润-14.74百万美元，同比增加3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558502923","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558502923?lang=zh_cn&edition=full","pubTime":"2025-08-10 00:01","pubTimestamp":1754755284,"startTime":"0","endTime":"0","summary":"8月10日，Ocugen, Inc.公布财报，公告显示公司2025财年第二财季净利润为-14.74百万美元，同比增加3.53%；其中营业收入为1.37百万美元，同比增加20.18%，每股基本收益为-0.05美元。从资产负债表来看，Ocugen, Inc.总负债50.54百万美元，其中短期债务853000.00美元，资产负债比为1.07，流动比率为1.83。机构评级：截至2025年8月10日，当前有4家机构对Ocugen, Inc.目标价做出预测，其中目标均价为6.50美元，其中最低目标价为4.00美元，最高目标价为8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000311a6dcb823&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250810000311a6dcb823&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCGN"],"gpt_icon":0},{"id":"2557934555","title":"Ocugen, Inc.盘中异动 下午盘股价大涨5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557934555","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557934555?lang=zh_cn&edition=full","pubTime":"2025-08-08 03:00","pubTimestamp":1754593219,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日03时00分，Ocugen, Inc.股票出现异动，股价急速上涨5.39%。Ocugen, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。其相关个股中，60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Cingulate Inc C/Wts 10/12/2026 、C4 Therapeutics, Inc.涨幅较大，Palisade Bio, Inc.、Bioxcel Therapeutics, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为1854.60%、221.52%、110.79%，振幅较大的相关个股有Palisade Bio, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Omniab Inc C/Wts ，振幅分别为105.51%、82.50%、59.72%。Ocugen, Inc.公司简介：Ocugen Inc 公司专注于发现、开发和商业化新型基因和细胞疗法和疫苗，以改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080803001994d61957&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080803001994d61957&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","BK4563","OCGN"],"gpt_icon":0},{"id":"2518126273","title":"Ocugen, Inc.盘中异动 股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518126273","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518126273?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:03","pubTimestamp":1741615429,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时03分，Ocugen, Inc.股票出现异动，股价大幅跳水5.03%。Ocugen, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Scisparc Ltd.、Dogwood Therapeutics, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为674.24%、343.91%、93.91%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Pmgc Holdings Inc.，振幅分别为41.36%、40.24%、32.14%。Ocugen, Inc.公司简介：Ocugen Inc公司专注于发现、开发和商业化新型基因和细胞疗法以及疫苗，旨在改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022034998a2a58a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022034998a2a58a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4563","BK4568","BK4139","OCGN"],"gpt_icon":0},{"id":"2518281638","title":"Ocugen, Inc.2024财年实现净利润-54.05百万美元，同比增加14.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518281638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518281638?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536046,"startTime":"0","endTime":"0","summary":"3月10日，Ocugen, Inc.公布财报，公告显示公司2024财年净利润为-54.05百万美元，同比增加14.32%；其中营业收入为4.06百万美元，同比减少32.78%，每股基本收益为-0.20美元。从资产负债表来看，Ocugen, Inc.总负债53.71百万美元，其中短期债务1.85百万美元，资产负债比为1.56，流动比率为2.86。机构评级：截至2025年3月10日，当前有4家机构对Ocugen, Inc.目标价做出预测，其中目标均价为6.75美元，其中最低目标价为4.00美元，最高目标价为8.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000112a2689808&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000112a2689808&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OCGN"],"gpt_icon":1},{"id":"2517157509","title":"Chardan Capital：维持Ocugen(OCGN.US)评级，由买入调整至买入评级, 目标价由6.00美元调整至7.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517157509","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517157509?lang=zh_cn&edition=full","pubTime":"2025-03-06 21:22","pubTimestamp":1741267337,"startTime":"0","endTime":"0","summary":"Chardan Capital：维持Ocugen(OCGN.US)评级，由买入调整至买入评级, 目标价由6.00美元调整至7.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06212248574267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["OCGN"],"gpt_icon":0},{"id":"2517044944","title":"Ocugen, Inc.盘中异动 股价大跌5.02%报0.560美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517044944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517044944?lang=zh_cn&edition=full","pubTime":"2025-03-06 00:37","pubTimestamp":1741192666,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日00时37分，Ocugen, Inc.股票出现异动，股价大幅下挫5.02%。截至发稿，该股报0.560美元/股，成交量173.376万股，换手率0.60%，振幅6.61%。Ocugen, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。Ocugen, Inc.公司简介：Ocugen Inc公司专注于发现、开发和商业化新型基因和细胞疗法以及疫苗，旨在改善健康并为全球患者带来希望。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306003746abe9d733&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306003746abe9d733&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4563","OCGN","BK4568"],"gpt_icon":1},{"id":"1138464321","title":"Ocugen 2024年第四季度GAAP每股亏损$(0.05)符合预期，营收$764,000超出$300,000预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1138464321","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138464321?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:14","pubTimestamp":1741176882,"startTime":"0","endTime":"0","summary":"Ocugen报告称，公司季度每股亏损$，符合分析师一致预期。这与去年同期每股亏损$相比下降了25%。公司报告季度营收为$764,000千美元，超出分析师一致预期的$300,000千美元，增幅达154.67%。以上内容来自Benzinga Earnings专栏，原文如下：$Ocugen$  reported quarterly losses of $ per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $764.000 thousand which beat the analyst consensus estimate of $300.000 thousand by 154.67 percent.  This is a 45.78 percent decrease over sal","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ocugen 2024年第四季度GAAP每股亏损$(0.05)符合预期，营收$764,000超出$300,000预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OCGN"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.ocugen.com","stockEarnings":[{"period":"1week","weight":-0.1006},{"period":"1month","weight":0.0362},{"period":"3month","weight":0},{"period":"6month","weight":0.4922},{"period":"1year","weight":0.9659},{"period":"ytd","weight":0.0593}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0179},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.099},{"period":"1year","weight":0.1555},{"period":"ytd","weight":0.0198}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ocugen, Inc.是根据马萨诸塞州的联邦法律注册成立于2000年6月28日，并在马萨诸塞州沃尔瑟姆进行主要业务运营。该公司是一家生物技术公司，专注于发现、开发新型基因和细胞疗法以及疫苗并将其商业化，这些疗法和疫苗可以改善健康并为全球患者带来希望。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.078212},{"month":2,"riseRate":0.333333,"avgChangeRate":0.428545},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.024731},{"month":4,"riseRate":0.454545,"avgChangeRate":0.068726},{"month":5,"riseRate":0.454545,"avgChangeRate":-0.04653},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.026339},{"month":7,"riseRate":0.545455,"avgChangeRate":0.125195},{"month":8,"riseRate":0.363636,"avgChangeRate":0.060461},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.186205},{"month":10,"riseRate":0.363636,"avgChangeRate":0.007831},{"month":11,"riseRate":0.272727,"avgChangeRate":-0.198584},{"month":12,"riseRate":0.545455,"avgChangeRate":0.383124}],"exchange":"NASDAQ","name":"Ocugen","nameEN":"Ocugen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ocugen(OCGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ocugen(OCGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ocugen,OCGN,Ocugen股票,Ocugen股票老虎,Ocugen股票老虎国际,Ocugen行情,Ocugen股票行情,Ocugen股价,Ocugen股市,Ocugen股票价格,Ocugen股票交易,Ocugen股票购买,Ocugen股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ocugen(OCGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ocugen(OCGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}